al knowledge.PO157|Self-Administration of Romiplostim in Patients with Persistent Immune Thrombocytopenia In contrast with Administration by a Healthcare Provider: Just one Center Knowledge F.J. L ez Jaime; A. Doblas M quez; E. Calavia Aranda; I. S chez Baz ; A. Monta BriosoPO155|Dentoalveolar Procedures in Immune Thrombocytopenia; Systematic Evaluate and Sensible RecommendationsUnidad de Hemostasia y Trombosis, D2 Receptor Agonist custom synthesis Hospital Universitario Regional de M aga, IBIMA, M aga, Spain Background: Primary immune thrombocytopenia (ITP) is often a disor-W.E.M. van Dijk1; R.J.J. van Es1; M.E.P. Correa2; R.E.G. Schutgens1; K.P.M. van Galen1der characterized by very low H2 Receptor Agonist list platelet counts (100 x109/L), which includes a substantial damaging affect on high-quality of daily life, work productivity and emotional well-being of individuals. Romiplostim can be a thrombopoietin receptor agonist used for the remedy of grownups with refractory ITP that’s administered weekly subcutaneously to boost platelet production. From the EU, the self-administration (SA) of romiplostim by sufferers and caregivers was accepted, demonstrating comparable amounts of efficacy and security to when administered by healthcare experts (HCP). Aims: To examine and assess the efficacy and security of romiplostim SA group with HCP group. Methods: Retrospective, observational and single-center examine of grownup sufferers with ITP taken care of with romiplostim. The efficacy endpoints incorporated percentage of individuals and weeks with platelets within the target variety of 5000 109/L with out the use of any rescue medicine and percentage of individuals with platelet counts 20 109/L or 400 109/L. Security was assessed from the incidence of treatment-related adverse occasions. Results: A complete of 33 sufferers (64.five females) were treated with romiplostim. The median age was 63 and 54.4 many years inside the SA (n = 21) and HCP (n = ten) groups, respectively. In each groups, a lot more than 90 of patients attained one platelet response. The median of remedy duration was 106 vs 46 weeks which has a very similar proportion of weeks using a platelet response (49.0 vs 47.15 ). Rescue medication was used in 57.9 and 37.5 of patients. Remedy discontinuation was thriving in 71.four and 75 . Two patients within the SAUniversity Healthcare Center Utrecht, Utrecht, Netherlands; 2Universityof Campinas, Campinas, Brazil Background: Dentoalveolar procedures in immune thrombocytopenia (ITP) pose a possibility of bleeding, on account of thrombocytopenia, and infection, due to immunosuppressive treatment options. Aims: To systematically review the safety and management of dentoalveolar procedures in ITP individuals so as to generate practical recommendations. Methods: Pubmed, Embase, Cochrane and Cinahl have been searched. All original scientific studies with surgical and non-surgical dentoalveolar procedures (which include tooth extractions, scaling, and periodontal and endodontic surgical treatment) in adult and pediatric sufferers with acknowledged key ITP at the time of procedure have been integrated. Facts on bleeding- and infection-related outcomes had been recorded, such as the therapeutic strategies. Clinically appropriate bleeding was defined as needing therapy or medical awareness. Outcomes: Eighteen posts were included, of which twelve situation reports/series. All round, the quality on the readily available evidence was bad. Outcomes and administered therapies (including hemostatic therapies and prophylactic antibiotics) weren’t systematically reported. No less than 118 dentoalveolar procedures in 94 ITP patients were described. The range of preoperative platelet co
